Gradalis, Mount Sinai announce research alliance

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Gradalis Inc. and the Icahn School of Medicine at Mount Sinai established a research alliance to advance the scientific understanding of the Gradalis Vigil Engineered Autologous Tumor Cell therapy.

Under the agreement, Gradalis will provide funding and clinical samples for studying the immune response to the therapy.

The research collaboration will be jointly headed by Gradalis’ Chief Scientific Officer John Nemunaitis and Seunghee Kim-Schulze, assistant professor of medicine and facility director, Human Immune Monitoring Core at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

The collaboration will span multiple clinical trials including the recently completed first in human study and ovarian phase 2A study. Additional collaboration efforts may be initiated to support ongoing registrational clinical trials in Ewing’s sarcoma and ovarian cancer, as well as trials exploring the combination of Vigil and PD-1/PDL-1 inhibitors in non-small cell lung cancer, melanoma and triple negative breast cancer.

With Vigil, a patient’s tumor cells are engineered with a plasmid carrying the gene vector for shRNA Furin and GMCSF to elicit a systemic T-cell directed immune response when administered to the patient through intradermal injections.

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login